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Robust expression of tumor suppressor
miRNA’s let-7 and miR-195 detected in
plasma of Saudi female breast cancer
patients
Amal Qattan1,2,3* , Haya Intabli1,3, Wafa Alkhayal4,5, Chafica Eltabache1, Taher Tweigieri6 and Suad Bin Amer1*
Abstract
Background: Female breast cancer is frequently diagnosed at a later stage and the leading cause of cancer deaths
world-wide. Levels of cell-free circulating microRNAs (miRNAs) can potentially be used as biomarkers to measure
disease progression in breast cancer patients in a non-invasive way and are therefore of high clinical value.
Methods: Using quantitative RT-PCR, circulating miRNAs were measured in blood samples collected from disease-
free individuals (n = 34), triple-negative breast tumours (TNBC) (n = 36) and luminal tumours (n = 57). In addition to
intergroup comparisons, plasma miRNA expression levels of all groups were analyzed against RNASeq data from
cancerous breast tissue via The Cancer Genome Atlas (TCGA).
Results: A differential set of 18 miRNAs were identified in the plasma of breast cancer patients and 10 miRNAs were
uniquely identified based on ROC analysis. The most striking findings revealed elevated tumor suppressor let-7 miRNA in
luminal breast cancer patients, irrespective of subtype, and elevated miR-195 in plasma of TNBC breast cancer patients. In
contrast, hsa-miR-195 and let-7 miRNAs were absent from cancerous TCGA tissue and strongly expressed in surrounding
non-tumor tissue indicating that cancerous cells may selectively export tumor suppressor hsa-miR-195 and let-7 miRNAs
in order to maintain oncogenesis.
Conclusions: While studies have indicated that the restoration of let-7 and miR-195 may be a potential therapy for
cancer, these results suggested that tumor cells may selectively export hsa-miR-195 and let-7 miRNAs thereby neutralizing
their potential therapeutic effect. However, in order to facilitate earlier detection of breast cancer, blood based screening
of hsa-miR-195 and let-7 may be beneficial in a female patient cohort.
Keywords: Circulating miRNAs, Triple-negative breast cancer (TNBC), Circulating biomarkers, Plasma versus tissue,
Secretion, FASN pathway, ROC curves, Cancer therapy
Background
The general consensus for breast cancer prevention and
treatment includes periodic breast cancer screening of
all women and the frequent monitoring of women at
higher risk [1]. Nevertheless, cancer statistics indicate
that as of January 2017 female breast cancer is the most
frequently diagnosed cancer [2]. Mammography is the
current gold standard for breast cancer screening and is
associated with significant discomfort which impedes
early detection [3]. Therefore, finding non-invasive, safe,
relatively inexpensive and accurate breast cancer tumor
markers [4] as well as potential blood-based biomarkers
for the diagnosis and prognostics of breast cancer [5–9]
remain important research objectives.
MicroRNAs (miRNAs) are short non-coding RNAs
which function as post-transcriptional regulators of gene
expression through targeted binding [10–12]. While tissue
biomarkers have been extensively studied in cancer detec-
tion, circulating miRNAs in body fluids, especially blood
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serum and plasma, are a promising source of stable
non-invasive biomarkers [13, 14]. The tumor specific
de-regulation of some miRNAs and their target genes
is frequently observed [15, 16] rendering some miR-
NAs as potential biomarkers for the diagnosis of can-
cer [13, 17, 18].
Despite the increase in the number of breast cancer
biomarker studies, due to the inconsistency of the results,
no consensus has been reached on the diagnostic use of
differentially regulated circulating miRNAs reported so far
[19]. Inconsistencies among studies may be due to patient
heterogeneity; genetic background, gender age, metabolic
status, as well as methodological challenges [19–24] such
as sample size, the number of miRNAs studied, blood col-
lection practices and isolation methods [22]. Moreover, co-
morbidities such as obesity and diabetes can significantly
affect plasma miRNA levels of putative cancer biomarkers
[25, 26]. Lastly, the miRNA detection method used, sample
type tested (plasma versus serum), and the use of either
spike-in or endogenous controls for normalization are the
major determinants of study outcomes, regardless of the
pathological condition in assessment [24].
Despite these challenges, this work on a purely Saudi,
female patient cohort to investigate whether a stable circu-
lating plasma miRNA signature could distinguish between
disease-free individuals (n = 34) and early stages diagnoses
of triple negative breast cancer (TNBC) (n = 36) and
luminal breast cancer tumor (n = 57). Due to the relatively
early diagnosis of cancer in this cohort, patient tissue biop-
sies were not available for analyses. Therefore, in order to
compare differences in miRNA expression levels in tumor
tissue versus plasma, plasma miRNA expression was com-
pared to publically available RNASeq data from cancerous
breast tissue and surrounding non-cancerous tissue avail-
able via The Cancer Genome Atlas (TCGA).
Methods
Ethical statement
Approval and written consent was obtained from all study
participants for the use of their blood samples for research
purposes. The study was approved by the Ethical Research
Committee and Basic Research Committee on Clinical
Research at KFSHRC, Riyadh, Saudi Arabia and was car-
ried out under the terms of the Helsinki Declaration.
Study cohort and clinical samples processing
A total of 127 females, disease-free individuals (n = 34),
triple-negative breast tumors (TNBC) (n = 36) and patients
with luminal tumors (n = 57) were recruited for the study.
All women were of Saudi background and recruited at the
King Faisal Specialist Hospital (KFSHRC). Details of the
study subjects with respect to the age of diagnosis, grade
and lymph node status are reported in (Additional file 1:
Table S1). All blood samples were obtained from patients
before any cancer therapy was administered. Blood sam-
ples were collected by vene-section in EDTA blood collec-
tion tubes (BD Vactainer, Plymouth, UK) and kept at 4 °C.
The blood was then centrifuged within 2 h at 1500 g at 4 °
C for 15 min to isolate the plasma. The plasma was col-
lected and centrifuged again at 2500 g at 4 °C for 15 min
(Heraeus multifug 3S-R-UK) to eliminate the debris. All
samples were stored at -80 °C.
Isolation of microRNA from plasma
RNA was isolated from the plasma using the miR-
Neasy Serum/Plasma Kit (Qiagen, Hilden, Germany),
following the manufacturer’s protocol with some
modifications. RNA isolation was performed in dupli-
cate. For the Qiagen kit assay, 1 ml of QIAzol lysis
reagent (Qiagen) was added to 200 μl of plasma
together with 1 μg of carrier MS2 RNA (Roche). The
samples were mixed and incubated for 5 min at room
temperature. To monitor the RNA isolation before
purification 3.5 μl (1.6 × 108 copies/μl) of C.elegans-
miR-39 miRNA mimic spike-in control was added
and 12 μg of pure glycogen was added as a carrier/
co-precipitant. Next, 200 μl of chloroform was added
to the starting sample and mixed for 15 s. Next, sam-
ples were incubated for 3 min at room temperature,
and centrifuged for 15 min at 12,000 g at 4 °C.
600 μl of the aqueous phase was transferred to a new
tube and 900 μl of 100% ethanol was added to the
spin column to allow all the RNA molecules to reach
the binding condition. After mixing, the samples were
transferred to RNeasy MinElute spin columns in a
2 ml collection tube and spun for 15 s at ≥8000 g.
The columns were washed with two buffers from
700 μl RWT buffer and then with 500 μl RPE buffer
(Qiagen, Hilden, Germany), with a short spin of 15 s
at ≥8000 g each time. Next, each column was washed
with 500 μl of 80% ethanol and centrifuged for 2 min
at ≥8000 g. Following 5 min high speed centrifuga-
tion, 14 μl of RNase-free water could be used for elu-
tion. All RNA samples were frozen at -80 °C until
further analysis.
Assessment of RNA quality and integrity
Quality of RNA was assessed by Nanodrop ND-2000
(Wilmington, DE, USA). Chromatographic characteris-
tics and integrity of all RNA samples were determined,
included interpretation of the peak detection of differ-
ent profiles, by means of RNA 6000 Nano LabChip,
(Agilent Technologies, Waldbronn, Germany), Agilent
2100 Bioanalyzer system (Agilent Technologies, Santa
Clara, USA) and the 2100 expert software tool (Agilent
Technologies, Santa Clara, USA).
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Quantitative real time polymerase chain reaction for
mature miRNA expression profiling [13, 27–29]
250 ng of the eluted RNA sample was used to make cDNA
using a miScript RT II kit with miScript HiSpec buffer from
Qiagen (Qiagen, Hilden, Germany). Briefly, the reaction
was set up in the thermal cycler for 60 min at 37 °C
followed by 5 min at 95 °C. The cDNA was then diluted
with 200 μl of RNase-free water. For RT-qPCR a total of
2750 μl was prepared, made up of (2 x QuantiTect SYBR
green PCR master mix, 10 x miScript universal primers
with a cDNA template and RNase free water). MicroRNAs
screening was performed using miScript miRNA PCR
Array Human Breast Cancer-MIHS-109Z (Qiagen, Hilden,
Germany). The miRNA PCR Array Panel contains 84 ma-
ture miRNAs most relevant to breast cancer tumorigenesis.
The final reaction volume was 25 μl per well, enough to
provide 1 ng cDNA per well. The plates were run following
a thermal cycling protocol: 95 °C for 15 min to activate the
HotStar Taq DNA polymerase, 40 amplification cycles of
15 s at 94 °C, 30 s at 55 °C, 30 s at 70 °C and at the end a
melting curve program. All qPCR reactions were run in
duplicate.
Data processing and statistical analysis
All samples passed ‘Positive PCR Controls’ (PPC) in which
the acceptable range of Ct values was set to 19 ± 2. Both
Reverse Transcription Controls (RTC) and (PPCs) were
used to assess whether there had been any inhibition dur-
ing the reverse transcription reaction. Avg CtmiRTC – Avg
CtPPC was calculated for each sample (Avg “average”). A
difference of greater than seven indicated impurities and
reaction inhibition, cellular contamination was assessed
using the mean Ct of the SNORNA (SNORD) controls.
Only the non-zero values were considered. SNORD72 was
excluded from computations as it performed poorly across
samples. A sample with a mean Ct < 32 was taken to indi-
cate cellular contamination. All samples used in the qRT-
PCR analysis were tested for quality and neither indication
of cellular contamination nor reaction inhibition was
detected. All samples collected were retained and none
discarded. For miRNA to be within the detection limit, the
Ct values were recommended to be between zero and 35.
Cel-correction to correct for technical variations that arise
during extraction procedure, exogenous spike-in controls
from C.elegans was used. The Qiagen miScript miRNA
PCR Array Human Breast Cancer array panel contains
two Cel-miR-39 spiked-in controls. The average Ct value
recorded in each sample for the spiked-in controls from
C.elegans, cel-39 was recorded and the median of average
Ct values (of all samples) was found. The normalizing fac-
tor for each sample was calculated by subtracting the me-
dian of all average Ctcel values from the average Ctcel value
for the sample. The ddCt computation (ΔΔCt) for each of
the three groups, the triple negative (TNBC) and the
luminal tumors, average dCt (ΔCt) was calculated for each
miRNA. The miRNAs with average dCt values (ΔCt)
below 15 and/or above 35 were excluded. ddCt (ΔΔCt) of
a given miRNA for a given pair of groups was computed
by finding the difference between the average dCt (ΔCt) of
the respective groups; for example, ΔΔCt(ddCt (Triple Nega-
tive vs. Controls)) = [Average dCt (TNBC)] – [Average dCt
(Controls)]. The relative expression of a given miRNA be-
tween any two groups was assessed by computing 2(−ddCt)
(2(−ΔΔCt)). A differential set was identified using the ddCt
(ΔΔCt) method proposed by Livak et al. [30]. The Mann-
Whitney unpaired test and Benjamin-Hochberg multiple
testing corrections were used to determine significant dif-
ferences in miRNA expression levels between groups [31].
All qPCR reactions were run in duplicate.
Bioinformatics analysis
The miRNA targets and the biological pathways they were
involved in were predicted using the microT-CDS
algorithm and mirPath v.2.0 available on the web-based
server DIANA. The micro-T threshold for target predic-
tion was set at 0.8 and targeted pathways were considered
significant at a p-value < 0.05 [32, 33]. Hierarchical clus-
tering was performed using GeneSpring GX 14.5.
Receiver operating characteristic (ROC) curves
Receiver Operating Characteristic (ROC) curves were gen-
erated using the web-based tool ROCCET [34] for finding
two sets of miRNAs that could best differentiate (i) triple-
negative tumour samples from normal (control) samples
and (ii) luminal tumour samples from normal (control)
samples. ROC (Receiver Operating Characteristic) curves
were then generated by Monte-Carlo Cross Validation
(MCCV). The procedure was performed repeatedly to cal-
culate the performance and confidence interval of each
model.
Comparison of miRNA levels in tissue and plasma
Since plasma levels of miRNA are not necessarily a
reflection of tissue levels [35–38] and tumor tissue was
not available from patients recruited for this study as
plasma was collected pre-cancer therapy, publicly avail-
able data from the TCGA (The Cancer Genome Atlas)
[39] was used to determine whether circulating plasma
levels were distinct from breast cancer tissue and
surrounding non-cancerous tissue levels. We compared
the observed miRNA plasma levels with the tissue levels
of corresponding miRNA precursors from the TCGA
study. The tissue level expression of miRNA precursors,
available as RPKM (reads per kilobase of transcript per
million) values was obtained for control samples (n =
87), luminal samples (n = 120) and Triple Negative sam-
ples (n = 38) from TCGA. The RPKM values of the pre-
cursors in tissue and the expression value for miRNAs
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in the current study were log2 transformed and auto-
scaled, to ensure the datasets are comparable.
Auto scaled value ¼ x−μð Þ=δ
The tissue RPKM and the plasma cel-corrected Ct
values are normalized to the mean (μ) and standard
deviation (δ) for each of the data. Since a miRNA pre-
cursor can give rise to an active form from each arm, we
compared both the 3′ and 5′ active forms were matched
to the same precursor. The 18 differentially expressed
active miRNA forms mapped to 17 precursor miRNAs
from TCGA. Then we analyzed the expression trends of
a given miRNA across tissue and plasma samples.
Results
Differences in circulating miRNAs between breast cancer
patients and normal samples
Comparative analysis identified an initial set of 18 circulat-
ing miRNAs (Table 1), which because of their differential
presence between the patient groups and healthy controls,
were further examined by cancer type. Figure 1 illustrates
relative expression of these 18 miRNAs subdivided into
three groups: TNBC plasma vs. disease free plasma (Group
A; n = 8 miRNAs: hsa-miR-29c-3p, hsa-miR-195-5p, hsa-
miR-210-3p, hsa-miR-19b-3p, hsa-miR-19a-3p, hsa-miR-
22-3p, hsa-miR-7-5p, hsa-miR-15a-5p); luminal patient
plasma vs. disease free plasma (Group B; n = 5 miRNAs:
hsa-let-7c-5p, hsa-miR-489-3p, hsa-miR-340-5p, hsa-miR-
199a-5p, hsa-miR-328-3p); lastly, all breast cancer patients
(irrespective of subtype) vs. disease free plasma (Group C;
n = 5 miRNAs: hsa-let-7i-5p, hsa-miR-25-3p, hsa-miR-16-
5p, hsa-let-7b-5p, hsa-miR-199a-3p).
Comparison of circulating miRNAs levels with cancerous
and non-cancerous tissue expression
Next, the tissue expression trends of the corresponding 17
miRNA precursors in relation to their active forms in
plasma were measured (Fig. 2). Since plasma collected from
all patients enrolled in this study occurred prior to chemo-
therapy administration and/or tumor biopsy, miRNA breast
cancer tissue and non-cancerous tissue expression values
Table 1 Fold change (FC) and p-values of the 18 significant miRNA
Triple Negative Luminal
miRNA ID 2^-(TNBC-
C)A
p (Corr) TNBC vs
CP
Regulation (TNBC vs
C)
FC (TNBC vs
C)F
2^-(L-
C)B
p (Corr) L vs C
P
Regulation (L vs
C)
FC (L vs
C)F
hsa-let-7b-5p 2.14 0.006 Up 2.14 2.29 0.000 Up 2.29
hsa-let-7c-5p 1.72 0.031 Up 1.72 1.95 0.001 Up 1.95
hsa-let-7i-5p 1.71 0.008 Up 1.71 1.60 0.008 Up 1.60
hsa-miR-15a-5p 2.01 0.006 Up 2.01 0.91 0.977 Up −1.09
hsa-miR-16-5p 2.20 0.000 Up 2.20 1.68 0.008 Up 1.68
hsa-miR-195-5p 1.84 0.004 Up 1.84 1.60 0.011 Up 1.60
hsa-miR-199a-
3p
0.36 0.002 Down −2.81 0.36 0.003 Down −2.80
hsa-miR-199a-
5p
0.46 0.021 Down −2.19 0.25 0.001 Down −3.94
hsa-miR-19a-3p 1.81 0.006 Up 1.81 1.29 0.205 Up 1.29
hsa-miR-19b-3p 1.86 0.006 Up 1.86 1.27 0.203 Up 1.27
hsa-miR-210-3p 1.91 0.000 Up 1.91 1.23 0.646 Up 1.23
hsa-miR-22-3p 1.93 0.006 Up 1.93 1.08 0.083 Up 1.08
hsa-miR-25-3p 2.02 0.001 Up 2.02 2.01 0.001 Up 2.01
hsa-miR-29c-3p 1.66 1.010 Up 1.66 1.19 0.203 Up 1.19
hsa-miR-328-3p 1.58 0.563 Up 1.58 20.96 0.000 Up 20.96
hsa-miR-340-5p 0.65 0.043 Down −1.54 0.55 0.008 Down −1.81
hsa-miR-489-3p 1.85 0.057 Up 1.85 2.26 0.000 Up 2.26
hsa-miR-7-5p 2.30 0.003 Up 2.30 2.01 0.012 Up 2.01
TNBC Triple Negative Breast Cancer
C - Disease-free individuals used as Controls
L - Luminal Breast Cancer
A: 2^-(TNBC-N) represents 2^ddCt values of Triple Negative patient’s samples as compared to those of disease-free individuals
P: Corrected p-values ≤ 0.01 for a given pair of conditions are shown in bold
F: Fold change values ≥ 1.5 are shown in bold
B: 2^-(L-N) represents 2^ddCt values of Luminal patients’ samples as compared to those disease-free individuals
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were obtained from publically available TCGA RNASeq
data; non-cancerous tissue samples (n = 87), luminal sam-
ples (n = 120) and Triple Negative samples (n = 38). Expres-
sion trends for some miRNAs (hsa-miR-19a, hsa-miR-19b,
hsa-miR-210, hsa-miR-16, hsa-miR-7 and to a certain ex-
tent hsa-miR-15a) were similar in both tissue and plasma.
Tissue and plasma levels of non-diseased controls com-
pared against both cancer patient groups showed a broad
reversal of the trend. For example, tumor repressor miRs
hsa-let-7c and hsa-miR-195 were significantly decreased in
both luminal and TNBC breast cancer tissue levels (TCGA)
and increased in non-tumor tissue samples. Slight varia-
tions of this pattern were observed for hsa-miR-489, hsa-
miR-328, hsa-miR-25, hsa-let-7i, hsa-let-7b, hsa-miR-29c,
hsa-miR-199a, hsa-miR-340 and hsa-miR-22.
Pathway analysis of target genes
Lastly, a pathway analyses was performed on the target
genes of the 18 differential miRNAs identified in this
study (Additional file 1: Figure S1). Not surprisingly, many
of them were involved in signaling functions, namely the
PI3K-Akt, mTOR, p53, TGF-beta, Wnt, FoxO, estrogen
signaling and Hippo signaling pathways. However, the
most significantly enriched pathways were the ECM-
receptor interaction (Extracellular Matrix) and the fatty
acid biosynthesis (FASN) pathways. Gene targets of the
let-7 family were found to be involved in ECM receptor
interaction while the fatty acid biosynthesis pathway
(FASN) was shown to be enriched mainly by hsa-miR-16-
5p, hsa-miR-15a-5p and hsa-miR-195-5p. Both hsa-miR-
15a-5p and hsa-miR-195-5p were enriched exclusively in
the plasma of TNBC patients (see Fig. 1).
Receiver operating characteristic (ROC) curves
In order to assess the potential of each of these miRNAs as
cancer biomarkers, we generated ROC curves. Since Uni-
variate AUC ROC curves looked promising, whether a
more robust prediction could be made using multiple miR-
NAs was explored. A panel of seven miRNAs consisting of
Fig. 1 Circulating miRNAs showing differential levels in breast cancer
patients (Triple negative and Luminal) with respect to disease-free
individuals. Three main groups: TNBC vs. healthy controls (Group A; eight
significantly regulated miRNAs); luminal patients vs. healthy controls
(Group B; five significantly regulated miRNAs); and breast cancer patients
irrespective of subtype and healthy controls (Group C; five significantly
regulated miRNAs)
Fig. 2 Comparison of miRNA levels in tissue and plasma. Hierarchical clustering view of the normalized expression levels of active forms of
miRNA. The tissue level expression of miRNA precursors available as RPKM (reads per kilobase of transcript per million) values were obtained from
TCGA RNASeq data as follows: control samples (n = 87), Triple negative breast cancer samples (n = 38) and Luminal samples (n = 120). The RPKM
values of the precursor in tissue and the expression value in the current qPCR (inferred as 2-dCt (2(−ΔCt))) for circulating miRNA, were log2
transformed and auto-scaled to ensure the data are comparable
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hsa-miR-199a-3p, hsa-miR-15a-5p, hsa-let-7c-5p, hsa-miR-
7-5p, hsa-miR-195-5p, hsa-miR-489-3p and hsa-let-7i-5p
showed the maximum discriminatory potential between
TNBC patient plasma and disease-free plasma (Fig. 3a).
Similarly, a panel of five miRNAs consisting of hsa-miR-
328-3p, hsa-miR-199a-3p, hsa-let-7i-5p, hsa-miR-195-5p
and hsa-miR-25-3p best predicted luminal tumor patients
from disease-free individuals (Fig. 3b). The Univariate
AUC statistic for each miRNA is provided (Additional file 1:
Table S2).
Discussion
In less developed countries, including those of the Middle
East, breast cancer accounted in 2012 for 25% of all
reported cancer cases in females. It has been estimated
that in 2020 more than 1.9 million women will be diag-
nosed with breast cancer, marking an increase of 18.4%
[40]. Given the expected increase in female breast cancer
diagnosis, the aim of this study was to discover whether
any putative circulating miRNA biomarkers, could be dif-
ferentially detected in the plasma of early stage, treatment-
naïve female breast cancer patients. Analyses were per-
formed on plasma isolated from healthy, cancer-free fe-
males (n = 34), cancer therapy naïve patients diagnosed
with triple-negative breast cancer tumors (TNBC) (n = 36)
and finally, cancer therapy naïve patients with luminal tu-
mors (n = 57). As patient tumor biopsies were not available
at the time of plasma collection, plasma miRNA expres-
sion levels in cancer groups were analyzed not only against
the plasma of healthy but also against publically available
RNASeq data from non-cancerous tissue samples (n = 87),
luminal samples (n = 120) and triple negative samples (n =
38), provided by the (The Cancer Genome Atlas (TCGA)).
It is exceptionally challenging to discuss the results of
miRNA biomarker studies in the context of the literature as
reports are very contradictory. A meta-analyses performed
by Leidner et al. [41] demonstrated major inconsistencies
in qPCR as well as genome-wide approaches for detecting
miR biomarkers. For example, with the exception of miR-
155 and miR-21, none of the 25 miRNAs analyzed by qPCR
by eight independent groups; whose cohort sizes were simi-
lar to the one used in this study, were detected to be in
agreement by more than one study. Furthermore, the find-
ings of significantly elevated circulating miR-155 and miR-
21 by qPCR in breast cancer were actually contradicted by
subsequent data reported by genome-wide approaches
leading to what Leidner refers to as a dampening of enthu-
siasm for miRNA biomarkers [41]. However, the relatively
pure genetic background of the patient population may in-
crease the likelihood of reproducibility as well as the possi-
bility for clinical biomarker application.
As described by Witwer et al. [19] and Chen et al. [42],
the composition of circulating miRNAs in cancer patients
is governed by the following: 1) active secretion and/or pas-
sive leakage of miRNA from tumor cells, 2) increased cellu-
lar production and secretion, 3) enhanced selective
secretion, and 4) changes in miRNA stability. Similarly,
down-regulation of miRNA in the plasma may indicate
reduced secretion, increased retention and/or possibly rep-
resent a general neoplastic state [19]. For these reasons as
well as the fact that biopsies from chemotherapy naïve pa-
tient were not available, the differentially regulated miRNAs
Fig. 3 Receiver-operating characteristic (ROC) curve analyses (a) Panel of 7 miRNAs consisting of hsa-miR-199a-3p, hsa-miR-15a-5p, hsa-let-7c-5p,
hsa-miR-7-5p, hsa-miR-195-5p, hsa-miR-489-3p and hsa-let-7i-5p showed the maximum discriminatory potential between triple negative tumors
and disease-free individuals. Similarly, a five miRNA (b) Panel consisting of hsa-miR-328-3p, hsa-miR-199a-3p, hsa-let-7i-5p, hsa-miR-195-5p and
hsa-miR-25-3p best differentiated luminal tumors patients from the disease-free individuals
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identified in the plasma samples in this study were com-
pared with tissue levels of miRNA precursors from The
Cancer Genome Atlas (TCGA) (Fig. 2).
This analysis performed on this patient cohort led to the
identification of three broad categories representing dis-
tinct expression patterns of miRNAs. The first category
consists of hsa-miR-19a, hsa-miR-19b, hsa-miR-210, hsa-
miR-15a, hsa-miR-16 and hsa-miR-7 which are overex-
pressed in TNBC tissues as well as plasma. Therefore,
these miRNAs may directly reflect TNBC tumor biology.
To date, many studies have confirmed hsa-miR-19a/b
oncogenic role in TNBC tumor biology by repressing
PTEN and activating NF-kB [43] and levels of circulating
miR-19 correlated with response to neoadjuvant epirubi-
cin + paclitaxel chemotherapy regimen in Stage II and III
patients with luminal A breast tumors [44]. In a Japanese
TNBC patient cohort, high hsa-miR-210 expression was
identified as an independent factor indicating poor prog-
nosis for TNBC [45]. In contrast, members of the miR-15
family have tumour suppressor properties. Hsa-miR-16-5p
and hsa-miR-15a-5p are involved in the cell cycle, differ-
entiation, proliferation, hormone regulation and immune
response [46]. Various studies reported their down-
regulation in most tumours [47]. However, miR-15 family
miRNAs are strongly regulated by hormones [48]. Given
their multiple functions and complicated regulation, it is
unlikely that miR-15 family members would make an suf-
ficient early biomarker for breast cancer. The second cat-
egory of miRNAs consisted of hsa-miR-199a and hsa-
miR-340 which were differentially regulated in tissue and
plasma. In contrast to the first group, these miRNAs were
decreased in breast cancer patient plasma compared to
healthy controls. The third category has several distinct
sub-groups. An inverse pattern between plasma and tissue
levels specific to TNBC patients was observed for hsa-let-
7b, hsa-miR-29c, and hsa-miR-22. In all cases the plasma
miRNAs levels were higher than the tissue levels, support-
ing evidence of cancer cell secretion of miRNAs.
The main finding of this study is that blood based
screening of has-miR-195 and let-7 may help to identify
and diagnose early stages of breast cancer patients. Ele-
vated circulating levels of let-7 family members (has-let-
7b, has-let-7c and has-let-7i) were observed. Studies
using breast cancer cell lines [36] and other cancer cell
lines [37] have reported the selective release of tumor
suppressor miRNAs into extra-cellular fluids. Therefore,
extra-cellular miRNAs are not merely the artefacts
excreted by dead tumour cells but key players assisting
in tumor development and metastasis by promoting
cancer-host cross talk [49]. As illustrated by Falcone et
al. [50], tumor cells use a multi-pronged approach to
create a metastatic niche by selectively secreting out tumor
suppressor miRNAs, thereby overcoming immune surveil-
lance by repressing the immune system and promoting
angiogenesis. Various members of the let-7 family have
been reported to be down-regulated in cancer tissues. Fur-
thermore, it has been shown that the restoration of let-7
levels in cells could be an effective cancer therapy [51].
Thus it is probable that breast cancer tumour cells select-
ively secrete tumor suppressor miRNAs to maintain onco-
genesis as suggested by Ohshima et al. [35]. Let-7 was also
increased in the TNBC patient plasma from an Irish
patient cohort [52] while in this population, let-7 was only
increased in luminal patients. In contrast, an Indian
cohort [53] observed decreased miR-195, and increased
Let-7 miRNA in circulating plasma of TNBC patients.
These highly variable results may be due to a variety of
patient variables such as metabolic status, age, cancer
stage; controls used, and may also highlight the influence
of genetic background on miRNA expression. At the time
of this manuscript revision, patient recruitment is cur-
rently ongoing for a robust blinded validation experiment.
Based on the pathway analysis performed in DIANA
[32, 33], the 18 miRNAs detected in this study and their
targets are extensively involved in FASN pathways,
ECM-receptor interaction, PI3K-Akt, mTOR, p53, TGF-
beta, Wnt, FoxO, estrogen signaling and Hippo signaling
pathways, all critical for carcinogenesis. Chen et al. [54]
reported hsa-miR-195-5p as a direct regulator of GLUT3
and the increased amounts of GLUT3 transcripts seem
to facilitate accelerated metabolism, high glucose re-
quirements, and increased glucose uptake in malignant
cells. Using cell lines, Singh et al. [55] demonstrated the
anti-cancer activity of hsa-miR-195 and suggested over-
expression of hsa-miR-195 as a potential therapy for
breast cancer. In this study, circulating hsa-mir-195
levels in TNBC plasma are higher than those in healthy
individuals. Likewise, an increased systemic miR-195
levels was observed in blood of breast cancer patients
[52, 56–58]. Non-cancerous TCGA tissue had high levels
of tumor suppressor hsa-miR-195 while TNBC cancer
tissue had low levels suggesting that hsa-miR-195 is se-
creted out of cancer cells, possibly to facilitate increased
GLUT3 expression.
Finally, in the panel of miRNAs selected for distinguish-
ing both TNBC and luminal patients from healthy con-
trols, the receiver operating characteristic (ROC) analysis
consistently included hsa-let-7 and hsa-miR-195. Com-
pared to cancer-free plasma samples, let-7 miRNA was
most elevated and associated with luminal breast cancer
diagnosis, irrespective of subtype, and miR-195 was ele-
vated in TNBC plasma and most associated with TNBC
breast cancer patients. In contrast, hsa-miR-195 and let-7
miRNAs were absent from cancerous TCGA tissue and
strongly expressed in surrounding non-tumor tissue indi-
cating that breast cancer tumor cells may selectively export
hsa-miR-195 and let-7 miRNAs. Taken together, these
observations suggest that any study evaluating the use of
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the over-expressed hsa-let-7 family and/or hsa-miR-195 as
anti-cancer therapy should consider that tumor cell ma-
chinery may actively target and excrete hsa-miR-195,
thereby neutralizing its anti-cancer effect [59, 60]. How-
ever, these miRNAs may be of potential use in the devel-
opment of a blood based screening test to complement
and improve early detection of breast cancer [58].
Conclusion
Plasma sampling from patients remains the least invasive
method for identifying biomarkers so any circulating
miRNA with disease specific expression would be advan-
tageous to clinicians. Breast cancer specific expression
requires that the putative biomarker expression remains
tightly linked to biological changes occurring during the
onset of tumor growth and through metastasis. Results
from this study suggest that both miR-195 and let-7
make satisfactory candidates for biomarkers. However,
since levels of let-7 have also been reported to be in-
creased in the serum/plasma of patients with other types
of cancer, a biomarker test alone would not be sufficient
to determine a diagnosis. However, let-7 may be a better
candidate than other miRs such as miR-15 or miR-29
which are regulated not only by the process of tumor-
genesis but also by hormones, which may lead to more
variability in results. Furthermore, while some studies
have indicated that the restoration of let-7 and miR-195
may be a potential therapy for cancer; this study found
that circulating hsa-miR-195 levels in TNBC plasma are
already significantly higher than those of healthy individ-
uals. These results also suggest that tumor cells may se-
lectively export hsa-miR-195 and let-7 miRNAs thereby
neutralizing their potential therapeutic effect [59, 60]. Fi-
nally, the model constructed by ROC of a panel of seven
miRNAs showed the maximum discriminatory potential
between TNBC patient plasma and disease-free plasma
while a panel of five miRNAs best predicted luminal
tumor patients from disease-free individuals. Future ex-
periments performed on this patient cohort should con-
firm findings in plasma, patient tissue, and track these
markers through the course of treatment (including tissue
from mastectomies) and during remission. While large
scale studies are necessary to confirm these results before
they can be applied into clinical practice, the miRNAs dif-
ferentially detected in the plasma of breast cancer patients
in this study warrant further investigation.
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